A pleasure to publish this at @CD_AACR w/some AMAZING @OncoAlert 🚨colleagues/friends SoMe has immense potential in ALL areas of medicine⚕️ ☑️raises awareness on trials ☑️promotes cancer prevention ☑️amplifies oncology info ☑️enables diverse viewpoints aacrjournals.org/cancerdisco…

FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma buff.ly/of0tajK The FDA 🇺🇸 has approved belzutifan in combination with pembrolizumab as adjuvant therapy for patients with clear cell renal cell carcinoma (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, including those with resected metastatic disease. The approval is based on the phase III LITESPARK-022 trial, where the combination significantly improved disease-free survival versus pembrolizumab alone (HR 0.72; p=0.0003), reducing the risk of recurrence, metastasis, or death by 28%. Overall survival data remain immature, while safety findings were consistent with the known profiles of both agents. Kudos to our @OncoAlert amazing Faculty Toni Choueiri & Tom Powles!! #KidneyCancer LITESPARK-022 buff.ly/joocKqx @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

🚨 FDA Approves capivasertib Plus Abiraterone as First Targeted Therapy for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer Source AstraZeneca buff.ly/ldFb96p The FDA has approved capivasertib in combination with abiraterone and prednisone as the first targeted therapy for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive #ProstateCancer . Approval was based on the Phase III CAPItello-281 trial, which demonstrated a 19% reduction in the risk of radiographic progression or death and improved median radiographic progression-free survival by 7.5 months. The decision also highlights the growing importance of biomarker-driven treatment and PTEN testing in advanced prostate cancer. @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

Dear Colleagues in #Prostate Cancer Introducing #APCCC26 Live from Lugano🇨🇭with @OncoAlert RT ADT ± ARPI in high-risk localized prostate cancer—where do we stand? Drs. Bertrand Tombal, Christopher Sweeney, and Jeff Michalski discuss patient selection, biomarkers, reimbursement challenges, pelvic nodal RT, and the evidence shaping treatment intensification. in this video: 👇 How should ARPIs be integrated into practice? Series Faculty @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin Pinging @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @amerseburger @brian_rini @declangmurphy @cdanicas @neerajaiims

The OncoAlert Horizons 🚨 1st Line reset & the new sequencing problem What do we want to achieve in HER2 met #BreastCancer ? Join @OncoAlert🚨Faculty @JavierCortesMD 🇪🇸 & @ElisaAgostinett 🇧🇪of @JulesBordet WATCH HERE👇 youtu.be/ON72fz0c4UI?si=65q-…

Construction and external validation of radiomics models to detect primary prostate cancer with machine learning: a multicenter study based on 68Ga-PSMA PET/CT sciencedirect.com/science/ar… Study evaluated machine learning–based radiomics models using 68Ga-PSMA PET/CT to noninvasively detect #ProstateCancer in 609 patients. An XGBoost-derived radiomics model combined with SUVmax demonstrated good diagnostic performance, achieving AUCs up to 0.921 for clinically significant prostate cancer and maintaining strong accuracy across external validation cohorts. These findings suggest that PSMA PET/CT radiomics could help assess prostate cancer risk and guide biopsy decisions. @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) nonsteroidal aromatase inhibitor (NSAI) in HR /HER2− early breast cancer (EBC) asco.org/abstracts-presentat… A biomarker 🎯 analysis from the phase III NATALEE trial evaluated baseline gene expression in over 3,000 patients with stage II/III HR /HER2− 🧬 early #BreastCancer Ribociclib plus endocrine therapy improved invasive disease–free survival consistently across all PAM50 intrinsic subtypes, regardless of genomic risk. Higher genomic risk and proliferation scores showed a trend toward greater benefit. Several baseline genes demonstrated potential predictive and prognostic value, further supporting adjuvant ribociclib across diverse HR /HER2− populations. @LoiSher @dradityabardia @ProfJohnCrown

Can we revisit immunotherapy after progression on first-line chemoimmunotherapy in ES-SCLC? 🤔 In this real-world study (n=151), ICI rechallenge was associated with: ✅ Higher ORR (26% vs 11.8%) ✅ Better disease control (75% vs 47.1%) ✅ Longer PFS2 (4.0 vs 2.4 months) ✅ Longer OS (9.4 vs 6.2 months) While prospective validation is still needed, these data suggest that selected patients who initially benefited from immunotherapy may still derive benefit from an ICI-based approach beyond progression @OncoAlert @StephenVLiu @GlopesMd @weoncologists @ManuelDomine @christine_lovly @OncoReporte @MedwatchKate @LungCancerEu

Current Status of PSMA-Targeted Agents Based on Small Molecules for Prostate Cancer in Preclinical Studies link.springer.com/article/10… PSMA is a validated target for #ProstateCancer imaging and radioligand therapy (RLT), with urea-based small-molecule ligands showing favorable pharmacokinetics, tumor penetration, and radiolabeling properties. Recent preclinical efforts aim to improve efficacy through ligand optimization, radionuclide selection, and pharmacokinetic enhancements. Strategies such as albumin-binding moieties and linker modifications seek to increase tumor uptake while reducing off-target toxicity. Therapeutic radionuclides, including lutetium-177, actinium-225, astatine-211, and iodine-125, offer complementary mechanisms of tumor cell destruction. @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Real-world data on post-neoadjuvant trastuzumab emtansine to benchmark DESTINY-Breast-05 and -11 emerging paradigms. asco.org/abstracts-presentat… In this real-world study of 187 patients with🧬 HER2-positive early #BreastCancer and residual disease after neoadjuvant therapy, post-neoadjuvant T-DM1 achieved excellent outcomes, with a 3-year invasive disease-free survival rate of 97% and only six recurrences after a median 30-month follow-up. @monicamilano84 @SaraGandini3 @darioT_ @antoniomarraMD @paolazagam @ValenzaCarmine @elisabettasabet @curijoey

RTOG 0848: neg overall, but benefit in pN0 (adj chemoRT improved OS 5yr 48% v 29%). Caveats: small N0 subgroup (N=91), gem chemo, pre neoadj era. My main takeaway: RT has role in (select) resectable PDAC & future trials need to focus on biologically favorable subset. @OncoAlert

#iTOX @GustaveRoussy Thanks #AurelienMarabelle for the invitation to present on long-term ICI tox, key priorities: - collect nuanced irAE data beyond clinical trial followup - time tox, financial tox, HRQOL - balancing tox response: "impact" @CancerCentreIre @OncoAlert #LCSM

Clinical correlation between metabolic biomarkers and chemoresistance in #gestationaltrophoblasticneoplasia 🩸 bit.ly/4v5hFsy @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

New Virtual Tumor Board on choroidal melanoma, a rare tumor of the eye with a high rate of metastasis to the liver, includes insight into the patient experience. Read this multidisciplinary report: acsjournals.onlinelibrary.wi… @OncoAlert @TuftsMedicalCtr @DanaFarber

🟦Nausea-Vomiting Prevention ESMO-MASCC 2023 guideline summary #cancer #oncology #MedX @OncoAlert @CancerCareMASCC

⚖️ A new editorial responds to a recent @AmericanCancer study on racial and rural disparities in cancer survival, and warns that proposed cuts to health care spending could widen these gaps. Editorial: acsjournals.onlinelibrary.wi… Related study: acsjournals.onlinelibrary.wi… @OncoAlert

Very important academic trial led by @ines_vazluis and her team at @GustaveRoussy to improve the care of young women with #BreastCancer…really grateful to have the chance to participate at @UniGenova #GallieraHospital in Genoa and looking forward to opening the study! @OncoAlert

Get expert insights on new #ProstateCancer data emerging from ASCO 2026. Prof. Evan Yu joins COR2ED live in Chicago to share his views on how new trial data presented at the meeting could impact the clinical management of patients with prostate cancer. Watch here👉 buff.ly/RtWHLjc

The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO shorturl.at/GzAe2, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial shorturl.at/26apO @TROGfightcancer @TOGAANZ to answer this question! #radonc

Dear Colleagues, Introducing a New Series from @APCCC_Lugano : #APCCC26 LIVE from Lugano In this Video Dr. Chris Sweeney , Tombal and Michalski discuss ⭐️RT ADT /- in high risk localized disease @BertrandTOMBAL @ChrisSweens1 @jmmrad @Silke_Gillessen @AOmlin @OncoAlert @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @EAntonarakis @KOSJ12 @DrRanaMcKay @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @EUplatinum

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) study Protocol bjui-journals.onlinelibrary.… The PATROL study is a multicenter, prospective screening trial evaluating #ProstateCancer early detection in individuals carrying germline 🧬 pathogenic variants linked to increased prostate cancer risk. The study assesses the predictive value of age-adjusted PSA 🧪 thresholds and prostate MRI for detecting clinically significant disease. Participants undergo annual screening, with biopsies triggered by predefined PSA levels or clinical concern. PATROL also collects biospecimens, clinical outcomes, and patient-reported data to advance biomarker development and risk-stratified screening strategies. @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists